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Disaggregated airway epithelial cells replicate in serum-free media containing supraphysiologic concen-
trations of insulin. To examine the hypothesis that the type 1 insulin-like growth factor (IGF) receptor
mediates the mitogenic action of insulin on these cells, we studied the mitogenic effects ofIGF-I and insu-
lin, and the expression of type 1 IGF receptors in primary cultures of adult canine tracheal epithelial cells.
Isolated tracheal epithelial cells were grown in varying concentrations of IGF-I or insulin in Ham's F12
medium supplemented with transferrin, cholera toxin, and endothelial cell growth supplement. Both IGF-I
and insulin increased DNA synthesis (measured as (3H]thymidine incorporation into DNA) and cell
number in a concentration-dependent fashion, but IGF-I was at least 20 to 60 times more potent than
insulin in its mitogenic effects. No additive or synergistic effect was observed with the simultaneous addi-
tion of IGF-I and insulin in maximally effective doses. A monoclonal antibody directed against the type 1
IGF receptor (aIR3) blocked the mitogenic activity of both IGF-I and insulin. Affinity labeling of type 1
IGF receptors by covalent cross-linking with disuccinimidyl suberate demonstrated the tracheal epithelial
cell IGF-I binding moiety to have a relative molecular weight of 130,000 D. Binding of (!ZSI]IGF-I to
this protein was inhibited by low concentrations ofIGF-I, relative to insulin, and by aIR3. An ll-kb tran-
script characteristic of mRNA for the type 1 IGF receptor was recognized in poly(A+)RNA derived from
cultured canine tracheal epithelial cells. These data demonstrate, by functional, biochemical, and molecu-
lar methods, that cultured canine tracheal epithelial cells express type 1 IGF receptors which mediate
their mitogenic response to IGF-I or supraphysiologic concentrations of insulin. These results also raise
the possibility that IGF-I may have an important role in growth and differentiation of large airways epi-
thelium.
The factors controlling airway epithelial growth and differ-
entiation during development and repopulation after injury
are not defined. Peptide growth factors have been implicated
in these processes (1). Evidence of a role for insulin-like
growth factor I (IGF-I) comes from the findings that it is syn-
thesized in the lung (2) and that type 1 IGF cell membrane
receptors have been demonstrated in lung tissue (3).
Supraphysiologic concentrations of insulin have been used
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to support the growth of a wide variety of epithelial cells, in-
cluding tracheal epithelium in vitro (4). In cells other than
pulmonary epithelia, high concentrations of insulin can in-
teract with the type 1 insulin-like growth factor receptor to
stimulate mitosis (5-7). We postulated, therefore, that in air-
way epithelia, insulin's effect on cell proliferation is also
mediated through the type 1 IGF receptor and that IGF-I is
a more potent mitogen for epithelial cells than insulin by vir-
tue of preferential binding to its high-affinity receptor. Toex-
amine these questions, we determined the mitogenic effects
of IGF-I using cultured canine tracheal epithelial cells in
defined, serum-free media, and examined the expression of
the type 1 IGF receptor by tracheal epithelial cells.
Materials and Methods
Materials
Cell culture-grade insulin, transferrin (TF), endothelial cell
growth supplement (ECGS), and cholera toxin (CT) were
obtained from Collaborative Research (Lexington, MA).
Ham's F12 and Eagle's minimum essential media (MEM)
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were from GIBCO (Grand Island, NY). Fetal bovine serum
(FBS) was obtained from Hyclone Laboratories (Logan,
UT). Protease XIV, trypsin, deoxyribonuclease (DNAse),
monoclonal anti-human myoglobin antibody, and bovine se-
rum albumin (BSA), fraction V (lot No. 88f-0071, IGF-I-
free) were purchased from Sigma Chemical Co. (St. Louis,
MO). Disuccinimidyl suberate was from Pierce (Rockford,
IL). Recombinant [Thr59]IGF-I was from Amgen Biologi-
cals (Thousand Oaks, CA). Guanidine thiocyanate was pur-
chased from Fluka (Ronkonkoma, NY), and cesium chloride
from Gallard-Schlesinger (Carle Place, NY). [Methyl-
3H]thymidine (sp act, 91 Ci/mmol), Na125I, and [a-32P]UTP
were obtained from Amersham (Arlington Heights, IL).
Monoclonal antibody against the type 1 IGF receptor (aIR3)
was a gift from 1. 1. Van Wyk and S. Jacobs (8). [J25I]-la-
beled IGF-I was prepared from recombinant IGF-I, purified
by immunoaffinity chromatography, and labeled by the chlo-
ramine T method (9). A human cDNA for the type 1IGF
receptor was obtained from American Type Culture Collec-
tion (No. 59294; Rockville, MD).
Isolation of Cells
Mongrel dogs were killed by an i.v, injection of pentobarbital
(125 mg/kg), tracheas removed, and tracheal epithelial cells
isolated as described by Wu and Smith (10). Briefly, connec-
tive tissue was removed and the tracheal segments were
rinsed in MEM and treated with 0.1% protease XIV and
0.01% DNAse in MEM for 16 h at 4 0 C. FBS (10%) was then
added, the mixture was agitated vigorously, and the disag-
gregated cells were filtered through Nitex mesh. The cells
were centrifuged at 500 X g for 10 min, the pellet washed
with MEM and 10% FBS, resuspended, and centrifuged
again .. The final pellet was resuspended in 5 % FBS and
Ham's F12 medium (F12) supplemented with penicillin (50
U/ml), streptomycin (50 U/ml) , and gentamicin (50 #tg/ml).
Cell viability was determined by exclusion of trypan blue,
and was consistently > 90 %. Tracheal epithelial cells iso-
lated by this technique are virtually free of fibroblast con-
tamination as judged by morphology and antikeratin immu-
nostaining (10). Serum-free conditions used after cell
attachment to plastic substrate do not support fibroblast sur-
vival (11).
. Culture Conditions
The disaggregated cells suspended in F12 with 5 % FBS were
plated in 24-well (16-mm-diam well) tissue culture plates
(Costar, Cambridge, MA) at a density of 2 x io cells/em',
After 24 h, the unattached cells were removed and the culture
medium was replenished with F12 supplemented with TF (5
#tg/ml),CT (0.01 #tg/ml), ECGS (7.5 #tg/ml), and various con-
centrations of insulin or IGF-I. Every other day, cells were
washed with F12 and fresh medium was added. All experi-
ments were performed using subconfluent monolayer cul-
tures, as judged by phase-contrast microscopy. Cell cultures
were maintained at 370 C in 95 % humidity and 5 % CO2.
Growth Properties of Canine Tracheal Epithelial Cells
Cells were grown on plastic culture plates in F12 with TF,
CT, and ECGS (control medium), or control medium sup-
plemented with insulin (860 nM or .10 #tg/ml) or IGF-I (13
nM or 100 ng/ml). Each day for 5 d, cells were removed
from four wells by trypsinization (0.1% trypsin and 1 mM
EDTA) and cell number was determined in quadruplicate by
electronic cell counting (Model ZBI; Coulter, Hialeah, FL).
The cell doubling time was calculated by the method of Chen
and Chen (12).
To determine the concentration relationship of the growth
response to IGF-I and insulin, freshly isolated tracheal epi-
thelial cells were plated in plastic multiwell plates and al-
lowed to attach over a 24-h period. The media was then
changed to provide F12 with TF, CT, and ECGS with multi-
ple concentrations of insulin or IGF-I. On the fifth day in cul-
ture, 1 #tCi of [methyl-Hlthymidine was added to the media.
Twenty-four hours later, the cells were removed by trypsiniza-
tion, and cell number and [methyPH]thymidine incorpora-
tion into DNA were determined. Cellular DNA was precipi-
tated in cold perchloric acid-methanol, the precipitant
recovered by centrifugation, and radioactivity of the pellet
measured (13).
The effect of the simultaneous addition of insulin and
IGF-I to canine tracheal epithelial cells was determined by
growing cells in control medium and 1.7 #tM insulin with
multiple concentrations of IGF-I. [MethyPH]thymidine
(1 p.Ci per well) was added 16 h before harvesting on the
sixth day. Cell number per well and tritiated thymidine in-
corporation into DNA were determined for each culture con-
dition. The same procedure was followed for tracheal epithe-
lial cells grown in control medium and 6.5 nM IGF-I with
multiple concentrations of insulin.
Inhibition of Type 1 IGF Receptor-ligand Binding
Canine tracheal epithelial cells were isolated as described
above, but after protease/DNAse treatment, 2.5% BSA was
added to the solution in place of 10% FBS to prevent possi-
ble interactions of serum components with cell surface re-
ceptors and antibody. The disaggregated cells were suspended
and plated in F12 with TF, CT, and ECGS (control medium).
After cell attachment, the cells were washed, and monoclo-
nal antibody directed against the IGF receptor (8) was added
to one half of the wells at a concentration of 550 nM (100
#tg/ml). Four hours later, additional media, control medium,
or control with either IGF-I (13 nM) or insulin (170 nM) was
added to paired groups of wells. After a 4-d incubation
period during which the culture media was not changed, the
cells were removed and cell number was determined by elec-
tronic cell counting. Exactly the same procedure was fol-
lowed using a monoclonal antibody directed against human
myoglobin (at the same molar concentration) to serve as an
isotypic control antibody.
Affinity Cross-linking Analysis
Previously described methods (14, 15) were used with the fol-
lowing modifications. Canine tracheal epithelial cells plated
at a density of 2 X lOS cells/em- on 60-mm plastic dishes
were incubated for 18 h in F12 with 5% FBS and then 3 d
with F12 plus control medium with 1.7 p.M insulin, as de-
scribed above. Media was then aspirated and the cell mono-
layer washed three times with 3 ml Hepes binding buffer (20
roM Hepes, pH 7.4, 120 roM NaCI, 5 roM KCI, 1.2 roM
MgS04 , 10 roM NaHC03, 1.3 roM CaC12, and 1.2 roM
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Figure 1. Phase-contrast microscopy of canine tracheal epithelial






















have the morphologic characteristics of epithelial cells . Fig-
ure 1 is a phase-contrast photomicrograph of these cells un-
der subconfluent conditions. Canine tracheal epithelial cells
cultured in Ham's F12 medium supplemented with TF, CT,
and ECGS did not proliferate, whereas with the addition of
either insulin (860 nM) or IGF-I (13 nM), their cell doubling
times were 109 ± 31 and 106 ± 41 h (mean ± SD; n =
4 or 5), respectively (Figure 2). Both IGF-I and insulin
stimulated a concentration-dependent proliferation of tra-
cheal epithelial cells (Figure 3). Each peptide produced an
20 40 60 80
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Figure 2. Growth of canine tracheal epithelial cells on plastic sub-
strate. Cells (2 x lOS cells/em') were plated in 24-well culture
plates and maintained in Ham's Fl2 with TF, CT, and ECGS (con-
trol medium) (circles), control with 860 nM insulin (squares), or
control with 13 nM IGF-I (triangles). Cell number per well was
determined in quadruplicate. Mean ± SEM are shown from a rep-
resentative experiment.
KH2P04) with 1% BSA (fraction V, IGF-I free; Sigma).
Cells were then incubated with ['2SI]-labeled IGF-I (6 x 1()5
cpm/dish) in Hepes binding buffer (with 1% BSA) with or
without various concentrations ofunlabeled IGF-I, insulin, or
monoclonal antibody at 8° C for 20 h. After incubation, the
media was aspirated and cells were washed with 3 ml ice-cold
Hepes buffer without BSA. Disuccinimidyl suberate (0.1mM)
in Hepes binding buffer without BSA was added for 15 min
at room temperature. The reaction was quenched by adding
9 ml of 10 mM Tris-HCl, pH 7.4, with 1 mM EDTA for 15
min. The solution was aspirated and the cells were solubilized
in 200 p.l of 2 % SDS, 0.05 M Tris-HCI, and 0.1 M UfT. The
cell lysates were removed by scraping with a rubber police-
man and transferred to microfuge tubes. The samples were
concentrated by evaporation (Savant, Farmingdale, NY) for
3 h to one-half their original volume and then boiled for 5
min. Sample proteins and [I'C]-labeled molecular weight
standards (myosin, M, = 200,000; phosphorylase b, M, =
100,000; BSA, M, = 69,000; ovalbumin, M, = 46,000; and
carbonic anhydrase, M, = 30,000) were separated using
10% SDS-PAGE (16). The gel was fixed in 10% acetic acid
and 30% methanol, washed, dried, and exposed to Kodak
AR5 film in the presence of Dupont Cronex Lightning Plus
intensifying screens at -70° C.
Northern Hybridization Analysis
IGF-I receptor cDNA corresponding to a 706-bp segment of
the a subunit was cloned into the EcoRl site of pBS+ (Strata-
gene, La Jolla, CA) and a (32P]-labeled antisense riboprobe
was in vitro transcribed using T7 RNA polymerase and [a-
32P]UTP (17). Subconfluent primary cultures of canine tra-
cheal epithelial cells, grown for 6 d after plating as described
above in plastic T-150 flasks in control medium with 1.7 p.M
insulin, were solubilized with 4 M guanidine thiocyanate
directly in culture flasks. Total cellular RNA was extracted
by centrifugation through a 5.7 M CsCl cushion (18) and
poly(A+)RNA isolated using oligo (dT) cellulose (19). Sam-
ples of poly(A+)RNA were denatured in glyoxal and dimethyl
sulfoxide at 50° C and size-fractioned by electrophoresis in
1% agarose gels. After capillary transfer to nylon mem-
branes (Gene Screen; New England Nuclear, Boston, MA)
(20); baking at 80° C, and UV cross-linking, the membrane
was prehybridized with buffer (6x SSC, 50 mM Tris-HCl,
pH 7.0, lOx Denhardt's reagent, and 50% formamide). Hy-
bridization to a [J2P]-labeled riboprobe was performed for
16 h at 65° C. After standard posthybridization washes in 50
mM NaCI, 20 mM NaHP04 , I mM EUfA, and 1% SDS at
55° C, the membrane was air-dried and exposed to Kodak
AR5 film with intensifying screens at -70° C for 16 h (21).
Statistics
Studies of tracheal epithelial cell growth and inhibition of
type 1 receptor binding were performed in quadruplicate for
each experiment. Analysis of variance with Thkey's method
of multiple comparison was used to compare data from ex-
periments with more than two samples. A P value <0.05 was
used for all tests .
Results
The canine tracheal epithelial cells studied are polygonal and
 



























































Figure 4. Additive effects of IGF-I and insulin on cell proliferation
and DNA synthesis in canine tracheal epithelial cells. Each point
is expressed as the mean ± SEM from quadruplicate wells in a rep-
resentative experiment from the same animal. Asterisks indicate
significant differences (P < 0.05) between cells incubated in the
presence and absence of insulin at the same IGF-I concentrations.
(a.) Cells initially plated in F12 with 5% FBS for 24 h were main-
tained in Ham's F12 plus TF, CT, ECGS, and either IGF-I and insu-
lin (1.7 1lM) (circles) or IGF-I alone (triangles). After 5 d of growth
in defined medium with media changes every other day, 1 JLCi/ml
[methyl-Hlthymidine was added to each well for a 16-h incuba-
tion. Methanol-perchloric acid-precipitated material was collected
and scintillation counting performed. (b.) Cells were treated as de-
scribed above. At the conclusion of the growth period, cell number
was determined using a Coulter counter. No differences were seen
among cells incubated with 1.71lM insulin and multiple IGF-I con-
centrations.
To determine if the effects of IGF-I's and insulin were ad-
ditive or synergistic, increasing concentrations ofIGF-I were
added to a concentration of insulin that stimulated mitosis.
As illustrated in Figure 4, no further increase in cell prolifer-
ation or DNA synthesis was observed when 13 nM IGF-I was
combined with 1.7",M insulin in the culture medium. Simi-
lar results were obtained when increasing doses of insulin
were added to a mitogenic concentration ofIGF-I (Figure 5).
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Figure 3.· IGF-I and insulin stimulation of DNA synthesis and cell
proliferation. Canine tracheal epithelial cells were initially plated
in Ham's F12 with 5 % FBS for 24 h, and then maintained for 6 d
in control medium and multiple concentrations of either IGF-I
(closed circles) or insulin (open circles) with media changes every
other day. Data points represent mean ± SEM of experiments using
tracheal epithelial cells from nine animals (each point represents
two to seven experiments, each performed in quadruplicate). (a.)
[MethyPH]thymidine incorporation into DNA. After 5 d of growth,
1 1lCifml [methyPH]thymidine was added to each well and in-
cubated another 16 h. Methanol-perchloric acid-precipitated mate-
rial was collected and scintillation counting performed. (b.) Tra-
oheal < epithelial cells were treated as described above. After a
6-d incubation, cells were harvested and counted using a Coulter
counter.
increase in DNA synthesis and cell number, but IGF-I was
more potent than insulin. The concentration of IGF-I re-
quired to affect proliferation was 20-fold lower than that of
insulin when half-maximal stimulation was calculated (3 nM
for IGF-I and 60 nM for insulin). Similar differences (60-
fold) were observed when thymidine incorporation was used
to calculate half-maximal stimulatory effects (3 nM for IGF-I
and 180 nM for insulin). No additional increase in thymidine
incorporation into DNA was seen with 100 nM IGF-I in a
single experiment. When the minimum dose required for
maximal proliferation was used as a measure of potency (l0
nM IGF-I versus 10 ",M insulin), IGF-I was approximately
1,000 times more potent than insulin.
 

















































Figure 6. Inhibition of cell proliferation by monoclonal antibody
to the type 1 IGF receptor. Cells were plated in 24-well plastic
plates in serum-free medium (F12 with TF, CT, and ECGS). After
a l-d incubation for cell attachment, monoclonal antibody to the
type 1 IGF receptor (aIR3, 550 nM) or control antibody (anti-
human myoglobin, 550 nM) was added to one-half of the wells.
Four hours later, additional media containing F12 with TF, CT, and
ECGS (control medium) or control with either IGF-I (13 nM) or
insulin (170 nM) was added to paired groups of wells. After 4 addi-
tional d of incubation, cell number was determined.
The effect of each antibody was studied in cells from two
animals; therefore, the proliferative response of each to insulin and
IGF-I was tested to determine if comparisons between the two cell
preparations was valid. Cell number per well (expressed x 10-4;
mean ± SD) measured at the conclusion of the growth period for
each condition was: control medium, 1.18 ± 0.09 and 2.21 ± 0.83
(P = 0.13); insulin (170 nM), 4.14 ± 0.43 and 4.69 ± 0.68 (P =
0.96); IGF-I (13 nM), 3.95 ± 0.26 and 4.50 ± 0.33 (P = 0.88) for
the isotypic antibody and aIR3, respectively. Because there were
no statistical differences between the two cell preparations, they are
shown together in this graph. In the respective experiments, aIR3
inhibited both insulin-stimulated and IGF-I-stimulated prolifera-
tion compared to cells incubated without antibody (P < 0.001),
while the isotypic antibody had no inhibitory effecton these param-
eters.
Results are expressed as the mean ± SEM. The shaded bars rep-
resent cells grown in the presence of aIR3 and open bars cells in-
cubated with control antibody. Asterisks denote significant differ-
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Figure 5. Additive effectsof insulin and IGF-I on cell proliferation
and DNA synthesis in canine tracheal epithelial cells. Each point
is expressed as the mean ± SEM from quadruplicate wells in a rep-
resentative experiment from the same animal. Asterisks indicate
significant differences (P < 0.05) between cells incubated in the
presence and absence of IGF-I at the same insulin concentrations.
(a.) Tracheal epithelial cells were initially plated in F12 with 5%
FBS for 24 h and then maintained in F12 plus TF, CT, ECGS, and
either insulin and IGF-I (6.5 nM) (triangles) or insulin alone (cir-
cles). After 5 d of growth in definedmedium, 1 JLCi/ml [methyPH]-
thymidine was added to each well for a 16-h incubation. Methanol-
perchloric acid-precipitated material was collected and scintillation
counting performed. (b.) Cells were treated as described above. At
the end of the growth period, cell number was determined using a
Coulter counter. No differences were seen among cells incubated
with 6.5 nM IGF-I and multiple insulin concentrations.
CONTROL INSULIN IGF-I
To investigate whether IGF-I's and insulin's mitogenic ac-
tions are mediated by binding to the type 1 IGF receptor, the
stimulatory effects of each were studied in the presence of
an antibody directed against this receptor. This antibody,
cdR3, has been shown to inhibit binding of both IGF-I and
insulin to the type 1 receptor (5, 6, 8). To control for any pos-
sible nonspecific effects of antibody addition to canine tra-
cheal epithelial cells, an isotypic antibody (to myoglobin)
was studied in an identical fashion. Figure 6 compares cell
growth in the presence of the isotypic control antibody and
anti-IGF receptor antibody and either insulin or IGF-I, as
well as in their absence. The proliferative response to IGF-I
and insulin was inhibited by alR3 in each case despite the
addition of sufficient concentrations of either IGF-I (13 nM)
or insulin (170 nM) to stimulate cell proliferation. The cellu-
lar proliferative response was not inhibited in the presence
of the same concentration of isotypic control antibody.
To confirm that IGF-I and insulin were interacting with
the type 1 IGF receptor, affinity labeling was performed by
cross-linking (1zSI]IGF-I with its binding moiety in the 'pres-
ence of various concentrations of IGF-I or insulin and mono-
clonal antibodies. Under reducing conditions, ['2SI]IGF-I was
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Figure 7. Affinitycross-linking ofIOF-I to canine tracheal epithe-
lial cells. Tracheal epithelial cells were incubated for 18 h at 80 C
with [125I]IOF-I in the absence (lane A) or the presence of unla-
beled IOF-I, 1.3 nM (lane B) or 13 nM (lane C) ; unlabeled insulin,
17 nM (lane D) or 1.7 JlM (lane E) ; or 550 nM monoclonal anti-
body, control anti-myoglobin (lane F) or anti-type 1 IOF recep-
torlexlR3 (lane G). The arrow points to the [12SI]IOF-I affinity-
labeled ex subunit of the type I IOF receptor. The labeled moiety
at about 40,000 D is an affinity-labeled IOF binding protein. Affin-
ity cross-linking was performed with 0.1 mM disuccinimidyl suber-
ate as described in MATERIALS AND METHODS. Shown are auto-
radiographs of the radioligand -receptor complexes analyzed by
PAOE under reducing conditions. The migration of molecular
weight standards is indicated on the left.
Figure 8. Northern hybridization of mRNA from canine tracheal
epithelial cells with human type 1 IOF receptor riboprobe . An au-
toradiograph of poly(A+)RNAfrom primary cultures of canine tra-
cheal epithelial cells hybridized with a p2P]-labeled human type I
IOF receptor riboprobe is shown. Lanes A and B contain 10 Jlgand
5 Jlg, respectively, of poly(N)RNA obtained from different ani-
mals. Cells had been isolated, plated , and grown for 5 d in Fl2 with
TF, CT, ECOS, and 1.7JlM insulin as described in MATERIALS AND
METHODS. The hybridizing band of 11 kb is indicated along with
molecular weight standards.
poly(A +)RNAfrom primary cultures of canine tracheal epi-
thelial cells was performed using a human IGF-I receptor
riboprobe. This riboprobe recognized an mRNA of about 11
kb (Figure 8), a transcript of the same size reported by others
in mRNA derived from mouse, rat (lung), and human tissue
(24, 25). This result demonstrates that epithelial cells from
canine trachea express a type 1 IGF receptor mRNA similar
to those previously described, indicating significant sequence
homology among species.
bound to a protein of about 130,000 D (Figure 7), a relative
size that corresponds to the binding subunit of both the type 1
IGF receptor and the insulin receptor (22). Complete inhibi-
tion of labeled peptide binding occurred with as little as 1.3
nM IGF-I, whereas 1,700 nM insulin was required to de-
crease the binding of [J2.5I]IGF-I. This result confirms that
the affinity-labeled moiety is the type 1 IGF receptor, rather
than the insulin receptor, and is consistent with the known
differences in receptor affinity for each peptide (23). Fur-
thermore, the type I IGF receptor monoclonal antibody
(aIR3) competed with labeled peptide, whereas control anti-
body had no effect. This result demonstrates that the inhibi-
tory effects of aIR3 are mediated by its interaction with the
type 1 IGF receptor.
To unequivocally confirm that canine tracheal epithelial
cells express type 1 IGF receptors, Northern analysis of
Discussion
We have demonstrated that canine trache~l epithelial cells in
primary culture express type 1 IGF receptors and that these
receptors mediate a mitogenic response. Expression of the
type 1 IGF receptor was demonstrated by functional, bio-
chemical, and molecular criteria. Namely, the response of
tracheal epithelial cells to IGF-I and insulin is consistent
with the relative affinities of each peptide to the type I IGF
receptor (23); the canine tracheal epithelial cell IGF-I bind-
ing moiety has a relative molecular size of the binding sub-
unit of the type 1 IGF receptor (about 140,000 D) (22), and
binding of labeled IGF-I to this protein is inhibited by low
concentrations of IGF-I, relative to those of insulin, and by
a monoclonal antibody that is specific to this receptor; and,
finally, an ll-kb transcript, characteristic of the mRNA for
the type 1 IGF receptor in other species (24, 25) , is recog-
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nized in poly(A +)RNA purified from canine tracheal epi-
thelial cells.
We have also demonstrated that the proliferative response
of canine tracheal epithelial cells to IGF-I and insulin is
mediated by the type 1 IGF receptor. IGF-I stimulates DNA
synthesis and cell proliferation in tracheal epithelial cells in
concentrations 20- to 60-fold lower than those required for
a similar response to insulin, a result consistent with the rel-
ative affinities of these peptides to the type 1 IGF receptor
(23). Furthermore, a monoclonal antibody specific for the
type 1 IGF receptor inhibits the response of canine tracheal
epithelial cells to both IGF-I and insulin. These results also
clarify why supraphysiologic concentrations of insulin stimu-
late cell proliferationin primary epithelialcell culture systems.
The selection of transferrin, endothelial cell growth sup-
plement, and cholera toxin as supplements to the culture
medium was determined, in part, by previous studies that
suggested that these factors were necessary for optimal ca-
nine tracheal epithelial cell growth (26). Despite the mito-
genic action of these supplements in other culture systems
(4), a combination of these factors was not sufficient to allow
tracheal cell proliferation without the addition of IGF-I or
high concentrations of insulin.
Our results are consistent with an in vivo role for IGF-I
in the stimulation of tracheal epithelial cell proliferation, be-
cause the nanomolar concentrations of IGF-I necessary to
stimulate tracheal epithelial cell proliferation are likely to be
within the physiologic range. Although lung tissue IGF-I
concentrations are not known in humans or dogs, human se-
rum concentrations are about 25 nM (27), while canine se-
rum concentrations average 10 nM (28).
The tracheal epithelial cell types responsive to mitogenic
stimulation are not known. Cells in this primary culture sys-
tem are not morphologically differentiated but can be in-
duced into ciliated and secretory cell types by manipulating
substrate and culture media supplements (11, 26). Because
basal cells and nonciliated cells have the shortest doubling
times in vivo (29), they appear to be the best candidates for
IGF-I responsiveness. Definitive demonstration of type 1
IGF receptors on specific epithelial cell types will require in
situ hybridization and immunocytochemistry correlated with
rigorous morphologic identification.
The lung is known to elaborate bioactive and immunore-
active IGF-I (30,31) and to express type 1 IGF receptors (3).
In the human fetus, a paracrine role for IGF-I has been postu-
lated based on the findings that lung mesenchymal elements
(septa, perivascular fibroblasts, and possibly interstitial cells)
possess mRNA for IGF-I (32), while IGF-I identified by im-
munocytochemistry is localized to airway epithelium (33).
Furthermore, Nakanishi and colleagues (34) recently showed
that small-cell lung carcinoma cell lines produce an IGF-I
precursor, proliferate in response to IGF-I, and demonstrate
growth inhibition in the presence of anti-IGF receptor mono-
clonal antibody, consistent with an autocrine mode of action.
Our study adds to the mounting evidence of a role for IGFs
in the growth of lung epithelial cells by demonstrating that
primary cultures of canine tracheal epithelial cells prolifer-
ate in response to IGF-I, an effectmediated by the type 1 IGF
receptor. These results prompt us to speculate that IGF-I
may be an important mitogen for the tracheal epithelium in
early life and after injury.
Acknowledgments: Wegratefully acknowledge advice and support from Dr. T. F.
Boat in the completion of this work, and the gift of the monoclonal antibody
alR3 from Drs. 1.1.VanWykand S. Jacobs. This work was supported by Grants
HL38902, HL34322, HD08299, and Training Grant HL07106-13from the Na-
tional Heart, Lung and Blood Institute and by the American Lung Association.
GZR is a recipient of the Harry Shwachman Clinical Investigator Awardof the
Cystic Fibrosis Foundation. Part of this work was completed during support
from a Thomas H. Davis Fellowship of the American Lung Association of North
Carolina. ADS is an Edward Livingston Trudeau Scholar. This article was
presented in part at the Annual Meeting of the American Thoracic Society, Las
Vegas, Nevada, May 1988.
References
1. James, R., and R. A. Bradshaw. 1984. Polypeptide growth factors. Annu.
Rev. Biochem. 53:259-292.
2. D'Ercole, A. J. 1987. Somatomedins/insulin-like growth factors and fetal
growth. J. Dev. Physiol. 9:481-495.
3. D'Ercole, A. J., D. B. Foushee, and L. E. Underwood. 1976. Somato-
medin-C receptor ontogeny and levels in porcine and human cord serum.
J. Clin. Endocrinol. Metab. 43:1069-1077.
4. Barnes, D., and G. Sato. 1980. Methods for growth of cultured cells in
serum-free medium. Anal. Biochem. 102:255-270.
5. Flier, J. S., P. Usher, and A. C. Moses. 1986. Monoclonal antibody to
the type I insulin-like growth factor (IGF-I) receptor blocks IGF-I recep-
tor-mediated DNA synthesis: clarification of the mitogenic mechanisms
ofIGF-I and insulin in human skin fibroblasts. Proc. Natl. Acad. Sci. USA
83:664-668.
6. Van Wyk, J. J., D. C. Graves, S. J. Casella, and S. Jacobs. 1985. Evidence
from monoclonal antibody studies that insulin stimulates deoxyribonu-
cleic acid synthesis through the type I somatomedin receptor. J. Clin. En-
docrinol. Metab. 61:639-643.
7. King, G. L., C. R. Kahn, M. M. Rechler, and S. P. Nissley. 1980. Direct
demonstration of separate receptors for growth and metabolic activities
of insulin and multiplication-stimulating activity (an insulinlike growth
factor) using antibodies to the insulin receptor. J. Clin. Invest. 66:130-
140.
8. Kull, F. C., S. Jacobs, Y. Su, M. E. Svoboda, J. J. Van Wyk, and P. Cua-
trecasas. 1983. Monoclonal antibodies to receptors for insulin and
somatomedin-C. J. Bioi. Chem. 258:6561-6566.
9. Van Wyk, J. J., M. E. Svoboda, and L. E. Underwood. 1980. Evidence
from radioligand assays that somatomedin-C and insulin-like growth
factor-I are similar to each other and different from other somatomedins.
J. Clin. Endocrinol. Metab. 50:206-208.
10. Wu, R., and D. Smith. 1982. Continuous multiplication of rabbit tracheal
epithelial cells in a defined, hormone-supplemented medium. In Vitro
18:800-812.
11. Van Scott, M. R., J. R. Yankaskas, and R. C. Boucher. 1986. Culture of
airway epithelial cells: research techniques. Exp. Lung Res. 11:75-94.
12. Chen, C., and S. C. Chen. 1981. Cell growth factor activity: new quantita-
tive method in cell culture assay. Exp. Cell Res. 136:43-51.
13. Stiles, A. D., B. T. Smith, and M. Post. 1986. Reciprocal autocrine and
paracrine regulation of growth of mesenchymal and alveolar epithelial
cells from fetal lung. Exp. Lung Res. 11:165-177.
14. Clemmons, D. R., V. K. M. Han, R. G. Elgin, and A. J. D'Ercole, 1987.
Alterations in the synthesis of a fibroblast surface-associated 35K protein
modulates the binding of somatomedin-C/insulin-like growth factor-I.
Mol. Endocrinol. 1:339-347.
15. Tollefson, S. E., R. Lajara, R. H. McCusker, D. R. Clemmons, and P.
Rotwein. 1989. Insulin-like growth factors (IGF) in muscle development:
expression ofIGF-I, the IGF-I receptor, and an IGF binding protein dur-
ing myoblast differentiation. J.Biol. Chem. 264:13810-13817.
16. Laemmeli, U. K. 1970. Cleavage of structural proteins during the assembly
of the head of bacteriophage T. Nature 227:680-685.
17. Schenbom, E. T., and R. C. Mierendorf, Jr. 1985. A novel transcription
property of SP6 and T7 RNA polymerases: dependence on template struc-
ture. Nucleic Acids Res. 13:6223-6236.
18. Chirgwin, J. M., A. E. Przybyla, R. J. MacDonald, and W. J. Rutter,
1979. Isolation of biologically active ribonucleic acid from sources en-
riched in ribonuclease. Biochemistry 18:5294-5299.
19. Aviv, H., and P. Leder. 1972. Purification of biologically active globin
gene messenger RNA by chromatography on oligo thymidilic acid cellu-
lose. Proc. Natl. Acad. Sci. USA 69:1408-1412.
20. Thomas, P. S. 1980. Hybridization of denatured RNA and small DNA
fragments transferred to nitrocellulose. Proc. Natl. Acad. Sci. USA 77:
5201-5205.
21. Lund, P. K., B. M. Moats-Staats, M. A. Hynesetal. 1986. Somatomedin-C/
insulin-like growth factor-I and insulin-like growth factor-Il mRNAs in
rat fetal and adult tissues. J. Biol. Chem. 261:14539-14544.
22. Chernausek, S. D., S. Jacobs, andJ. J. Van Wyk. 1981. Structural similar-
ities between human receptors for somatomedin C and insulin: analysis
by affinity labeling. Biochemistry 20:7345-7350.
23. Casella, S. J., V. K. M. Han, A. J. D'Ercole, M. E. Svoboda, andJ. J.
 
234 AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY VOL. 3 1990
Van Wyk. 1986. Insulin-like growth factor II binding to the type I somato-
medin receptor: evidence for two high affinity binding sites. J. Biol.
Chern. 261:9268-9273.
24. Ullrich, A., A. Gray, A. W. Tam et al. 1986. Insulin-like growth factor
I receptor primary structure: comparison with insulin receptor suggests
structural determinants that define functional specificity. EMBO J. 5:
2503-2512.
25. Lowe, W. L., M. Adamo, H. Werner, C. T. Roberts, and D. LeRoith.
1989. Regulation by fasting of rat insulin-like growth factor I and its
receptor: effects on gene expression and binding. J. Clin. Invest. 84:
619-626.
26. Van Scott, M. R., N. P. Lee, J. R. Yankaskas, and R. C. Boucher. 1988.
Effect of hormones on growth and function of cultured canine tracheal epi-
thelial cells. Am. J. Physiol. 225(Cell Physiol. 24):C237-C245.
27. Zapf, J., H. Walter, and E. R. Froesch. 1981. Radioimmunological deter-
mination of insulinlike growth factors I and II in patients with growth dis-
orders and extrapancreatic tumor hypoglycemia. J. Clin. Invest. 69:
1321-1330.
28. Eigenmann, J. E., D. E. Patterson, and E. R. Froesch. 1984. Body size
parallels insulin-like growth factor I levels but not growth hormone secre-
tory capacity. Acta Endocrinol. (Copenh.) 106:448-453.
29. Evans, M. J., and S. G. Shami. 1989. Lung cell kinetics. In Lung Cell Biol-
ogy. D. Massaro, editor. Dekker, New York. 1-36.
30. Snyder, J. M., and A. J. D'Ercole. 1987. Somatomedin C/insulin-like
growth factor I production by human fetal lung tissue maintained in vitro.
Exp. Lung Res. 13:449-458.
31. D'Ercole, A. J., G. T. Applewhite, and L. E. Underwood. 1980. Evidence
that somatomedin is synthesized by multiple tissues in the fetus. Dev.
Biol. 75:315-328.
32. Han, V. K. M., A. J. D'Ercole, and P. K. Lund. 1987. Cellularlocalization
of somatomedin (insulin-like growth factor) messenger RNA in the human
fetus. Science 236: 193-197.
33. Han, V. K. M., D. J. Hill, A. J. Strain et al. 1987. Identification of
somatomedin/insulin-like growth factor immunoreactive cells in the hu-
man fetus. Pediatr. Res. 22:245-249.
34. Nakanishi, Y., J. L. Mulshine, P. G. Kasprzyk et al. 1988. Insulin-like
growth factor I can mediate autocrine proliferation of human small cell
lung cancer cell lines in vitro. J. Clin. Invest. 82:354-359.
 
